Department of Pediatrics, College of Medicine, Seoul National University, Seoul, Korea, Republic of (South). RATIONALE: Compliance is a major component of successful medical treatment. However, non-compliance remains a barrier to effective delivery of healthcare worldwide. METHODS: Twenty healthcare facilities (secondary or tertiary hospitals) belonging to the Korean Academy of Pediatric Allergy and Respiratory Diseases (KAPARD) participated. Questionnaires were given to patients currently receiving treatment in the form of inhaled or oral or transdermal patch for mild to moderate asthma. RESULTS: A total of 1838 patients responded to the questionnaire. Mean age was 5.98 6 3.79 years (range: 0-18 years). With help from their caregivers, the percentage of patients that answered ''taking as prescribed'' was 38.04% for inhalant users, 50.09% for oral medication users, and 67.42% for transdermal users. Transdermal patch users had significantly greater compliance when compared to the other two groups (p<0.001). 34.15% of inhalant users, 70.33% of oral medication users, and 93.00% of transdermal patch users felt that their medication delivery system was ''Easy'' or ''Very easy'' to use (p<.001). ''Method of administration'' was deemed to be the most difficult part of the treatment regimen to follow, and 76.7% of patients preferred once-daily administration (i.e., ''Frequency of administration''). CONCLUSIONS: Asthma medication compliance in young children was found to be better in the transdermal patch group. This may be due to requiring fewer doses and easy to follow instructions. From a compliance point of view, the transdermal patch seems more useful for long-term asthma control in children compared to oral or inhaled medicine.
282
A Real-life study on efficacy of fixed-dose combination inhaled corticosteroids/longacting beta agonists therapy delivered by dry powder inhalers to combined therapy delivered by pressurized metered dose inhalers for Asthma Mona Sulaiman Al-Ahmad, MD FAAAAI; Kuwait University, Kuwait, Kuwait and Nermina A. Arifhodzic, PhD, MOH, Kuwait City, Kuwait. RATIONALE: There is limited evidence of the effectiveness of the combination of a long-acting beta agonist (LABA) with an inhaled corticosteroid (ICS) for asthma patients by pressurized metered dose inhalers (pMDIs) in real-life practice in Kuwait. The objective of this study is to examine the impact of inhaler device on real-life effectiveness by comparing ICS/LABA pMDIs versus DPIs. METHODS: A prospective ongoing study including adult active asthma patients. All patients were advised by their physician to continue with current treatment (DPI cohort) or to switch to pMDI (pMDI cohort). An interim analysis of the baseline, 3, and 12 months' follow-up data was conducted. RESULTS: At baseline 116 & 118 patients were included in the pMDI and DPI cohort, respectively. Asthma was uncontrolled in 31.0% in the pMDI cohort and 16.9% in the DPI cohort at baseline. The FEV 1 at baseline was similar for both cohorts (80.1 pMDI and 77.5 DPI) and at 3 months this slightly increased in the pMDI cohort (82 patients) to (81.7) and slightly decreased in the DPI cohort (112 patients) to (75.1). This was more pronounced for the PEF: from 351.7 to 362.8 to 370.5 (at 1-year) in pMDI and 367.2 to 349.9 to 308.2 (at 1-year) in DPI cohort. CONCLUSIONS: Overall improved outcomes of efficacy as measure by FEV1, PEF, ACT score with both devices. No major differences in efficacy between pMDI and DPI devices for asthma. Further data is needed before recommending any mode of delivery of ICS/LABA in Kuwait.
